Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis

Clinical Therapeutics, 2016 05; 38(5): 1205-1216. e-pub ahead of print 2016/04/06

To assess the economic outcomes and treatment patterns among patients with rheumatoid arthritis (RA) who used 1, 2, or 3 or more conventional synthetic disease-modifying antirheumatic drugs (DMARDs) before receiving a biologic therapy.

View abstract


Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ